Induction of angiogenesis represents one of the major hallmarks of cancer. The growth of new vessels is crucial to provide malignant
cells with an adequate supply of oxygen and nutrients. It is generally accepted that vascular endothelial growth factor (VEGF) is a
major driver of the angiogenic process in physiological and pathological processes in both embryo and adult. VEGF is often found overexpressed
in tumors, as well as its receptors VEGFR1 and VEGFR2. Hence, several different strategies have been designed to target
VEGF signal transduction. In the last decades, multiple inhibitors have been therapeutically validated in preclinical models and several
clinical trials. Neutralizing monoclonal antibodies against VEGF and small molecule tyrosine kinase inhibitors targeting VEGFRs have
been shown to block its angiogenic activity, resulting in tumor vascular regression, anti-tumor effects and improvements in patient survival.
However, side effects and lack of efficacy in some instances challenge the potential clinical impact of these therapies. This review
examines the role of VEGF signaling in cancer and outlines the current status of anti-angiogenic therapies against VEGF pathway.
Keywords: Vascular endothelial growth factor, angiogenesis, cancer, targeted therapies, Bevacizumab.
Rights & PermissionsPrintExport